Trial: 201809141

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year of Initial Treatment



Principal Investigator

Vij, Ravi

Disease Site

Multiple Myeloma

Learn more about this study at: